Skip to content

PanACEA

  • Contact us
  • Twitter
  • News
  • About Us
    • Mission
    • History
    • Governance
    • Donors
    • Scientific Network
  • Tuberculosis
    • Impact
    • Treatment
    • Drug development
  • Clinical Studies
    • Trial Design
    • PanACEA Studies
    • Vision for future Studies
  • Capacity Development

Pan-African Consortium for the Evaluation of Antituberculosis Antibiotics

We are faced with a global pandemic of tuberculosis and new tools to control this disease are needed urgently. We believe that new and old optimized drugs are central to any control strategy and the fastest route to tuberculosis elimination.

More..

Latest news

Staggered dosing of rifampicin using to minimise tolerability problems and maximize efficacy

PanACEA team together with collaborators at Uppsala University recently published a model-based study further elucidating how to optimally dose rifampicin. The work suggest that a staggered approach, starting a bit lower and then increasing doses, may improve the tolerability for patients and thereby enable the higher doses which we demonstrated earlier is beneficial in terms…

Read more Staggered dosing of rifampicin using to minimise tolerability problems and maximize efficacy

SUDOCU headline results presented at CROI

On Tuesday 20 February 2023 our PanACEA colleague Dr Norbert Heinrich presented the headline-results from the PanACEA SUDOCU study at the 30th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle – the largest and most important conference on  HIV and related conditions such as tuberculosis. SUDOCU investigated safety and efficacy of varying doses of…

Read more SUDOCU headline results presented at CROI

PanACEA & SimpliciTB Annual Meeting, Mangochi, Malawi, 20th-22nd September 2022

Finally, after 2 years due to COVID-19, the PanACEA and SimpliciTB family were reunited in Malawi, hosted by Dr Marriott Nliwasa, Kamuzu University of Health Sciences at Makokola Retreat, Mangochi.  The hospitality and organisation of all of the teams made it  a very successful and enjoyable meeting. PanACEA The first day started with a variety…

Read more PanACEA & SimpliciTB Annual Meeting, Mangochi, Malawi, 20th-22nd September 2022

STATUS update: SUDOCU completed recruitment!

The PanACEA SUDOCU study completed its recruitment: a total of 75 participants were randomized to 5 arms (15 participants each) with a wide range of sutezolid doses (from 0mg to 800mg BID given over three months). With this open-label, randomized, phase 2B, dose selection study (ClinicalTrials.gov identifier NCT03959566) we aim to describe the safety/tolerability-exposure relationship…

Read more STATUS update: SUDOCU completed recruitment!

Shorter treatment may be possible with higher rifampicin doses

An interview with prof. dr. Martin Boeree A considerably higher dose of the anti-tuberculosis drug rifampicin has been found to be safe according to a recent publication by PanACEA. Higher dosing of rifampicin may lead to a shorter / more efficacious treatment for tuberculosis with less resistance development. With this finding PanACEA researchers complete a…

Read more Shorter treatment may be possible with higher rifampicin doses

Tweets by PanACEA_II
© PanACEA
  • edctp
  • European Union
  • This project is part of the
    EDCTP2 programme supported
    by the European Union

  • Contact us
  • Twitter